EW vs REPL
Edwards Lifesciences Corp (EW) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported EW revenue for 2024-12-31 was $1.39B. Net income was $385.6M. Revenue was up 2.3% from 2024-09-30 to 2024-12-31. EW currently screens at market cap $49.91B and trailing P/E 46.9.
REPL does not have a complete income-statement cache yet.
EW currently screens at market cap $49.91B and trailing P/E 46.9. REPL currently screens at market cap $825.7M.
Not investment advice. Open the EW and REPL stock pages for the full models.
Not investment advice.